Is Erdafitinib currently successfully marketed in China?

Erdafitinib is a targeted therapy drug mainly used to treat patients with urothelial cancer such as advanced or metastatic bladder cancer, especially those carrying FGFR gene mutations. At present, erdafitinib has been successfully approved for marketing in China, which is an important new treatment option for domestic FGFR-positive tumor patients. However, since the drug has just been sold in the Chinese market, its actual supply in hospital pharmacies is still being gradually rolled out, and some areas may not be able to purchase it directly for the time being.

Although erdafitinib is already on the market in China, it has not yet been included in the national medical insurance directory, so the cost of the drug still needs to be borne by patients themselves. Due to the short time to market, the domestic selling price is unclear and there may be regional differences. Therefore, if patients need to purchase erdafitinib, it is recommended to consult the hospital pharmacy or professional medical platform in advance to obtain accurate drug supply information and pricing.

In overseas markets, the original drug of erdafitinib is mainly the version sold in Hong Kong, China. The specifications are generally 4mg or 5mg. The price is higher, and a box of medicine may cost more than 20,000 yuan. Because this drug is an original research product, its efficacy and safety have been verified by multiple clinical trials, and it is suitable for patients who have the conditions and urgent need for medication. However, it should be noted that when purchasing through Hong Kong pharmacy channels, you should ensure that the source is legitimate to avoid purchasing counterfeit or expired drugs.

In addition, many foreign countries have launched generic drugs of erdafitinib, such as the Laos version and the Bangladesh Yaopin International version. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, but are more affordable, ranging from a few hundred yuan to more than 2,000 yuan per box. For patients with limited financial resources or who are temporarily unable to obtain original drugs, generic drugs provide a more feasible treatment path. When choosing, it is still recommended to purchase and use drugs rationally under the guidance of a professional doctor to ensure the safety and effectiveness of the medication.

Reference link:https://www.balversa.com/